Campbell & CO Investment Adviser LLC Purchases New Shares in Gilead Sciences, Inc. $GILD

Key Points

• Campbell & CO Investment Adviser LLC acquired a new position in Gilead Sciences, purchasing 28,810 shares valued at approximately $3.23 million.
• Gilead Sciences reported quarterly earnings of $2.01 EPS, surpassing analyst estimates, with revenue of $7.08 billion for the quarter.
• The company recently announced a quarterly dividend of $0.79, representing an annual yield of 2.8% and a dividend payout ratio of 62.95%.

Campbell & CO Investment Adviser LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 28,810 shares of the biopharmaceutical company's stock, valued at approximately $3,228,000.

Several other large investors have also bought and sold shares of GILD. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences in the first quarter valued at about $25,000. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences during the first quarter worth about $29,000. Colonial Trust Advisors grew its holdings in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Core Alternative Capital increased its stake in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares during the period. Finally, IMA Advisory Services Inc. acquired a new position in Gilead Sciences in the 1st quarter valued at approximately $39,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target for the company in a research report on Tuesday, August 19th. UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research note on Friday, July 25th. Royal Bank Of Canada lifted their price objective on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Finally, Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $115.39.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares in the company, valued at $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock valued at $9,339,230 in the last ninety days. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Down 0.7%

GILD traded down $0.83 during trading on Wednesday, hitting $113.92. The company's stock had a trading volume of 4,663,278 shares, compared to its average volume of 6,572,293. Gilead Sciences, Inc. has a twelve month low of $77.23 and a twelve month high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The stock's fifty day moving average price is $112.71 and its 200-day moving average price is $109.32. The firm has a market capitalization of $141.35 billion, a P/E ratio of 22.69, a PEG ratio of 0.70 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period in the previous year, the firm earned $2.01 earnings per share. The company's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's payout ratio is 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.